Tag: BAVENCIO
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Featured Article
The future of sports manufacturing: Inside M2M Group’s AI-powered strategy
As the sports manufacturing industry evolves, artificial intelligence (AI) is emerging as a critical catalyst for innovation and efficiency.
